» Articles » PMID: 37570684

Pyronaridine As a Bromodomain-Containing Protein 4--Terminal Bromodomain (BRD4-BD1) Inhibitor: Database Mining, Molecular Docking, and Molecular Dynamics Simulation

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Aug 12
PMID 37570684
Authors
Affiliations
Soon will be listed here.
Abstract

BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone proteins and promotes the transcription of genes linked to cancer progression and non-cancer diseases such as acute heart failure and severe inflammation. The highly conserved -terminal bromodomain (BD1) recognizes acylated lysine residues to organize the expression of genes. As such, BD1 is essential for disrupting BRD4 interactions and is a promising target for cancer treatment. To identify new BD1 inhibitors, a SuperDRUG2 database that contains more than 4600 pharmaceutical compounds was screened using techniques. The efficiency of the AutoDock Vina1.1.2 software to anticipate inhibitor-BRD4-BD1 binding poses was first evaluated based on the co-crystallized R6S ligand in complex with BRD4-BD1. From database screening, the most promising BRD4-BD1 inhibitors were subsequently submitted to molecular dynamics (MD) simulations integrated with an MM-GBSA approach. MM-GBSA computations indicated promising BD1 binding with a benzonaphthyridine derivative, pyronaridine (SD003509), with an energy prediction (Δ) of -42.7 kcal/mol in comparison with -41.5 kcal/mol for a positive control inhibitor (R6S). Pharmacokinetic properties predicted oral bioavailability for both ligands, while post-dynamic analyses of the BRD4-BD1 binding pocket demonstrated greater stability for pyronaridine. These results confirm that studies can provide insight into novel protein-ligand regulators, specifically that pyronaridine is a potential cancer drug candidate.

Citing Articles

Docking‑based virtual screening of BRD4 (BD1) inhibitors: assessment of docking methods, scoring functions and in silico molecular properties.

Dong J, Hao X BMC Chem. 2024; 18(1):247.

PMID: 39696643 PMC: 11657568. DOI: 10.1186/s13065-024-01362-5.


Repurposing of drug candidates against Epstein-Barr virus: Virtual screening, docking computations, molecular dynamics, and quantum mechanical study.

Ibrahim M, Hassan A, Mohamed E, Mekhemer G, Sidhom P, El-Tayeb M PLoS One. 2024; 19(11):e0312100.

PMID: 39546470 PMC: 11567563. DOI: 10.1371/journal.pone.0312100.

References
1.
Han Y, Zhang J, Hu C, Zhang X, Ma B, Zhang P . ADME and Toxicity Prediction of Ceftazidime and Its Impurities. Front Pharmacol. 2019; 10:434. PMC: 6491819. DOI: 10.3389/fphar.2019.00434. View

2.
Dahlgren D, Lennernas H . Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. Pharmaceutics. 2019; 11(8). PMC: 6723276. DOI: 10.3390/pharmaceutics11080411. View

3.
Pires D, Blundell T, Ascher D . pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9):4066-72. PMC: 4434528. DOI: 10.1021/acs.jmedchem.5b00104. View

4.
Garbuzenko O, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T . Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J Control Release. 2019; 296:225-231. PMC: 6461390. DOI: 10.1016/j.jconrel.2019.01.025. View

5.
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith W, Fedorov O . Selective inhibition of BET bromodomains. Nature. 2010; 468(7327):1067-73. PMC: 3010259. DOI: 10.1038/nature09504. View